Skip to main content

Table 1 Baseline characteristics, VZV disease characteristics and impact on immunosuppressive treatment

From: Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression

Baseline characteristics

VZV disease characteristics

Impact on immunosuppressive treatment

Case

Sex/Age (years)

Diagnosis

Medication at onset of VZV

VZV vaccine doses

Time to event (months)

Date of onset

Rash

Complications

Hosp.

Treatment

Dur.

Management of immunosuppression

Varicella

       

  1

F/4.8

JIA

MTX

0

15.1

05/2004

typical

cellulitis

6d

ACV i.v. + AB

7d

unknown

  2

F/6.3

JIA

MTX

0

14.9

06/2005

typical

none

no

no

-

continued

  3

F/6.3

JIA

MTX

0

14.2

01/2006

typical

none

no

no

-

continued

  4

F/3.0

JIA

MTX

0

6.2

01/2007

typical

none

no

no

-

continued

  5

F/6.1

JIA

MTX + INF

0

17.6

02/2008

typical

cellulitis, sepsis

9d

ACV i.v. + AB

7d

interrupted

  6

F/3.7

JIA

ETA

0

4.2

02/2009

typical

none

no

ACV i.v.

n.a.

interrupted

  7

F/3.4

JIA

MTX + ETA

0

8.6

04/2009

typical

none

no

no

-

interrupted

  8

F/2.5

JIA

ETA

0

4.4

03/2010

typical

cellulitis

no

ACV p.o. + AB

7d

continued

  9

F/17.4

JIA

MTX

1

29.9

10/2010

typical

none

no

no

-

continued

  10

M/8.9

JIA

MTX + ADA

0

21.7

02/2011

typical

cerebellitis

5d

ACV i.v.

7d

continued

  11

M/8.8

JIA

MTX + INF

0a

5.7

04/2011

atypical

none

no

no

-

continued

  12

F/7.2

JIA

MTX

0

3

02/2012

typical

none

5d

ACV i.v.

5d

interrupted

  13

F/6.2

JIA

MTX + TCZ

0

1.1

03/2012

atypical

none

no

ACV p.o.

8d

interrupted

  14

M/4.0

JIA

MTX

0

12.4

04/2012

atypical

none

no

VCV p.o.

7d

interrupted

  15

M/4.1

JIA

TCZ + Pred.

0

3.2

06/2012

typical

none

6d

ACV i.v.

6d

interrupted

  16

M/7.5

JIA

MTX + INF

1

30.3

04/2013

atypical

none

no

ACV i.v. + p.o.

7d

interrupted

Herpes zoster

       

  17

F/6.4

JIA

MTX

0

5.5

04/2004

n.a.

none

no

no

-

continued

  18

F/14.7

JIA

MTX + ADA

0

10.9

10/2004

n.a.

none

no

no

-

continued

  19

F/5.9

JIA

MTX

0

4.1

01/2005

n.a.

none

no

no

-

continued

  20

M/13.6

PAS III

RTX + Pred.

0

6

12/2008

n.a.

none

no

no

-

continued

  21

F/9.5

JIA

LEF + INF

0

27.6

07/2011

Lumbar 1, left

none

no

VCV p.o.

n.a.

interrupted

  22

F/16.5

Ant. Uv.

MTX + INF

0

63

11/2013

Trigeminal ophthalmic nerve, left

none

4d

ACV iv. + p.o.b

7d

interrupted

  1. ahad a history of varicella at the age of 6 months. Hosp hospitalization, Dur duration, MTX methotrexate, ETA etanercept, INF infliximab, ADA adalimumab, TCZ tocilizumab, Pred prednisone, VCV valaciclovir, ACV aciclovir, AB antibiotics; balso received local aciclovir. LEF leflunomide, RTX rituximab, JIA juvenile idiopathic arthritis, Ant. uv anterior uveitis, PAS polyglandular autoimmune syndrome, n/a not available